Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis

Infection and Immunity

Volumn 70, Issue 6, 2002, Pages 3026-3032

  Vordermeier, H Martin ^a   Chambers, Mark A ^a   Cockle, Paul J ^a   Whelan, Adam O ^a   Simmons, Jennifer ^a   Hewinson, R Glyn ^a  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CFP 10 ANTIGEN; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; MYCOBACTERIUM ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; BCG VACCINATION; CATTLE DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; CATTLE; INTERFERON TYPE II; MYCOBACTERIUM BOVIS; TUBERCULOSIS, BOVINE; VACCINATION;

EID: 0036266656     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.6.3026-3032.2002     Document Type: Article

References (53)

1. Joint WHO/FAO expert committee on zoonoses, second report
2. Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis
3. Compartmentalization of a CD4+ T lymphocyte subpopulation in tuberculous pleuritis
4. Field experiment with BCG vaccine in Malawi
5. Incidence of tuberculosis in BCG vaccinated and control cattle in relation to age distribution in Malawi
6. Differentiation between Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle using recombinant mycobacterial antigens
7. Experimental Mycobacterium bovis infection of cattle: Effect of dose of M. bovis and pregnancy on immune responses and distributions of lesions
8. Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG
9. Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae
10. + T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis
11. Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis
12. Disseminated tuberculosis in interferon gamma gene-disrupted mice
13. Epidemiology of Mycobacterium bovis infection in animals and humans, with particular reference to Africa
14. Pathogenesis of pulmonary tuberculosis: An interplay of tissue-damaging and macrophage activating immune responses-dual mechanisms that control bacillary multiplication
15. T-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts
16. Circulating profile of Th1 and Th2 cytokines in tuberculosis patients with different degrees of pulmonary involvement
17. First results of the field use of BCG vaccine to control bovine tuberculosis in Malawi
18. A second experiment to challenge the resistance to tuberculosis in B.C.G. vaccinated cattle in Malawi
19. EEC directive 80/219, amending directive 64/432 annexe B
20. The BCG story: Lessons from the past and implications for the future
21. Immunology of tuberculosis
22. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection
23. Immune responses in tuberculosis
24. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG
25. Mycobacterium bovis in England and Wales: Past, present and future
26. Vaccination of calves against tuberculosis with Calmette-Guerin culture BCG
27. The immunity conferred by effective BCG and vole bacillus vaccines, in relation to individual variations in induced tuberculin sensitivity and to technical variations in the vaccines
28. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis
29. Untersuchungen zur tuberkuloseschutzimpfung bei rindern
30. Protective effect of DNA immunization against mycobacterial infection is associated with the early emergence of interferon-gamma (IFN-gamma)-secreting lymphocytes
31. Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: Implications for primate models in tuberculosis vaccine research
32. Comparative analysis of T lymphocytes recovered from the lungs of mice genetically susceptible, resistant, and hyperresistant to Mycobacterium tuberculosis-triggered disease
33. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-γ in their lungs
34. The immunogenicity of single and combination DNA vaccines against tuberculosis
35. Human deficiencies in type 1 cytokine receptors reveal the essential role of type 1 cytokines in immunity to intracellular bacteria
36. Predominant recognition of the ESAT-6 protein in the first phase of interferon with Mycobacterium bovis in cattle
37. Distinct response kinetics for gamma interferon and interleukin-4 in bovine tuberculosis
38. Pulmonary mononuclear cell responses to antigens of Mycobacterium tuberculosis in healthy household contacts of patients with active tuberculosis and healthy controls from the community
39. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis
40. Different cytokine patterns correlate with the extension of disease in pulmonary tuberculosis
41. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis
42. IFN-gamma and IL-12 are increased in active compared with inactive tuberculosis
43. Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities
44. Intradermal immunization with a bovine herpesvirus-1 DNA vaccine induces protective immunity in cattle
45. Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in the Gambia
46. Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment
47. Towards the development of diagnostic assays to discriminate between Mycobacterium bovis infection and BCG vaccination in cattle
48. Development of diagnostic reagents to differentiate between Mycobacterium bovis BCG vaccination and M. bovis infection in cattle
49. Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle
50. An experiment to challenge the resistance to tuberculosis in BCG vaccinated cattle in Malawi